Recent prospective of surface engineered Nanoparticles in the management of Neurodegenerative disorders

Abstract

Clinically, the therapeutic outcomes in neurodegenerative disorders (NDs) by drug treatment are very limited, and the most insurmountable obstacle in the treatment of NDs is the blood-brain barrier (BBB), which provides the highest level of protection from xenobiotics. A great deal of attention still needs to be paid to overcome these barriers, and surface-engineered polymeric nanoparticles are emerging as innovative tools that are able to interact with the biological system at a molecular level for the desired response. The present review covers the potential importance of surface-structure-engineered nanoparticles to overcome the BBB for good bioavailability, and the evaluation of drug therapy in NDs.

Co-encapsulation of superparamagnetic nanoparticles and doxorubicin in PLGA nanocarriers: Development, characterization and in vitro antitumor efficacy in glioma cells

“…Controlled and continued release of the drug in the tumor area could thus increase the tumor drug concentration and avoid the usual side effects. For instance, it has been widely demonstrated that nanosystems formed with the assistance of surfactant Tween 80 (T80) increase the amount of drug that reaches the brain [9][10][11]. In the bloodstream the T80nanosystems are covered with apolipoprotein A or B and then endocytosed by the lowdensity lipoprotein (LDL) receptors, which are highly expressed in the BBB/BBTB cells [12].…”

Drug delivery in overcoming the blood–brain barrier: role of nasal mucosal grafting

“…These nanocarriers can have an organic or inorganic core and a surface coating with organic moieties able to interact with the biological system at a molecular level for crossing the BBB. 31 …”

Brain aging and Parkinson’s disease: New therapeutic approaches using drug delivery systems

“…Systemic delivery of certain DDS has the potential to cross the BBB and target specific brain regions. Coating DDS with surfactants such as polysorbate 80, dextran or polyethylene glycol (PEG) has been recently reviewed concerning neurodegenerative disorder applications [42]. Taking advantage of BBB endogenous receptors appears to be a suitable strategy to cross the BBB.…”